Previous studies in prostate cancer were mostly conducted with FASN inhibitors such as C75, orlistat, and triclosan [53, 54, 55], whose off‐target effects as well as instability and poor solubility/oral availability have limited their use in the clinical setting [56]. The gene discussed is FASN; the disease is Familial prostate cancer.